These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 31016431

  • 1. Causes of late transplant failure in cyclosporine-treated kidney allograft recipients.
    Moroni G, Binda V, Quaglini S, Sacchi L, Raffiotta F, Cosa F, Montagnino G, Favi E, Messa P, Ponticelli C.
    Clin Exp Nephrol; 2019 Aug; 23(8):1076-1086. PubMed ID: 31016431
    [Abstract] [Full Text] [Related]

  • 2. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B, Canver B, Gurlek Demirci B, Colak T, Ozdemir BH, Haberal M.
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [Abstract] [Full Text] [Related]

  • 3. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 5. One-Year Multicenter Double-Blind Randomized Clinical Trial on the Efficacy and Safety of Generic Cyclosporine (Iminoral) in De Novo Kidney Transplant Recipients.
    Khatami SM, Taheri S, Azmandian J, Sagheb MM, Nazemian F, Razeghi E, Shahidi S, Sadri F, Shamshiri AR, Sayyah M.
    Exp Clin Transplant; 2015 Jun; 13(3):233-8. PubMed ID: 26086833
    [Abstract] [Full Text] [Related]

  • 6. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
    Roodnat JI, Hilbrands LB, Hené RJ, de Sévaux RG, Smak Gregoor PJ, Kal-van Gestel JA, Konijn C, van Zuilen A, van Gelder T, Hoitsma AJ, Weimar W.
    Transplantation; 2014 Jul 15; 98(1):47-53. PubMed ID: 24521775
    [Abstract] [Full Text] [Related]

  • 7. Effects of late cyclosporine withdrawal on renal graft function and survival.
    Pagonas N, Yusefi K, Seibert FS, Bauer F, Markakis K, Sasko B, Zidek W, Götze T, Schlattmann P, Viebahn R, Babel N, Westhoff TH.
    J Nephrol; 2019 Apr 15; 32(2):315-321. PubMed ID: 30443763
    [Abstract] [Full Text] [Related]

  • 8. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T, Yoshimura N, Ushigome H, Watarai Y, Nishimura K, Akioka K, Nakamura N, Kawakita M, Yuzawa K, Nakatani T.
    Int J Urol; 2018 Feb 15; 25(2):141-145. PubMed ID: 29068092
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B, Bridson JM, Halawa A.
    Exp Clin Transplant; 2016 Oct 15; 14(5):471-483. PubMed ID: 27213490
    [Abstract] [Full Text] [Related]

  • 10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep 15; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 11. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR, Hakemi MS, Esfehani F, Alatab S, Naderi GH.
    Iran J Kidney Dis; 2013 Jul 15; 7(4):309-15. PubMed ID: 23880809
    [Abstract] [Full Text] [Related]

  • 12. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 15; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 13. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R.
    Transplantation; 2017 Jan 15; 101(1):157-165. PubMed ID: 26950714
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients.
    Garrouste C, Kamar N, Guilbeau-Frugier C, Guitard J, Esposito L, Lavayssière L, Nogier MB, Cointault O, Ribes D, Rostaing L.
    Exp Clin Transplant; 2012 Apr 15; 10(2):110-8. PubMed ID: 22432753
    [Abstract] [Full Text] [Related]

  • 15. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR.
    Transplantation; 2016 Aug 15; 100(8):1723-31. PubMed ID: 27306529
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 15; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 17. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 15; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 18. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr 15; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 19. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.
    Azarfar A, Ravanshad Y, Mehrad-Majd H, Esmaeeli M, Aval SB, Emadzadeh M, Salehi M, Moradi A, Golsorkhi M, Khazaei MR.
    Saudi J Kidney Dis Transpl; 2018 Apr 15; 29(6):1376-1385. PubMed ID: 30588970
    [Abstract] [Full Text] [Related]

  • 20. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E, Harber M, Bhagani S, Levy J, Jones R, Hilton R, Davies G, Post FA, UK HIV Kidney Transplantation Study Group.
    Transplantation; 2016 Apr 15; 100(4):871-8. PubMed ID: 26413990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.